Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | PLUMMB: final results of pembrolizumab & hypofractionated RT in bladder cancer

Robert Huddart • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Urothelial Carcinoma Antibodies Checkpoint Inhibitors Pembrolizumab
PLUMMB

Robert Huddart, PhD, FRCR, MBBS, MRCP, The Institute of Cancer Research, London, UK, discusses final findings from the Phase I PLUMMB trial (NCT02560636), evaluating the safety, tolerability, and efficacy of pembrolizumab combined with hypofractionated radiotherapy (RT) in advanced bladder cancer. Results confirm that 24 Gy in 6 fractions with pembrolizumab is well tolerated and effective, which highlight the potential of immunoradiotherapy in bladder cancer treatment. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robert Huddart

The role of immunotherapy after radiation in bladder cancer
1:11
The role of immunotherapy after radiation in bladder cancer
Robert Huddart • 13 Feb 2025
RE-ARM: radiotherapy as an immune-priming strategy in bladder cancer
1:46
RE-ARM: radiotherapy as an immune-priming strategy in bladder cancer
Robert Huddart • 13 Feb 2025
The role of erdafitinib in treating patients with bladder cancer
2:20
The role of erdafitinib in treating patients with bladder cancer
Robert Huddart • 22 Oct 2023
Challenges of delivering radiotherapy for bladder preservation in patients with bladder cancer
1:42
Challenges of delivering radiotherapy for bladder preservation in patients with bladder cancer
Robert Huddart • 22 Oct 2023

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals